Cyclacel Pharmaceuticals Return on Equity

Cyclacel Pharmaceuticals (CYCC) currently reports a ROE of -22.34%. That is below the Healthcare sector average of 21.67%. Use the charts on this page to explore Cyclacel Pharmaceuticals's ROE history and peer comparisons.

Cyclacel Pharmaceuticals's ROE of -22.34% is lower than the Healthcare sector average of 21.67%. That is roughly 203.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Cyclacel Pharmaceuticals's current -22.34% should be judged against Healthcare norms (sector average: 21.67%) and against CYCC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -22.34%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Cyclacel Pharmaceuticals, and consider following CYCC for alerts when major investors trade the stock.

Cyclacel Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows -22.34% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CYCC with unrelated industries.